{
  "pmcid": "5884950",
  "config": {
    "model": "gemini",
    "strategy": "few-shot"
  },
  "usage": {
    "input": 18341,
    "output": 449
  },
  "raw_text": "{\n  \"extractions\": [\n    {\n      \"outcome\": \"objective-SCORAD score\",\n      \"intervention\": \"extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).\",\n      \"comparator\": \"extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": 13,\n      \"comparator_events\": null,\n      \"comparator_group_size\": 13,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    },\n    {\n      \"outcome\": \"chemokines CXCL9\",\n      \"intervention\": \"extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).\",\n      \"comparator\": \"extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).\",\n      \"outcome_type\": \"continuous\",\n      \"intervention_events\": null,\n      \"intervention_group_size\": 21,\n      \"comparator_events\": null,\n      \"comparator_group_size\": 20,\n      \"intervention_mean\": null,\n      \"intervention_standard_deviation\": null,\n      \"comparator_mean\": null,\n      \"comparator_standard_deviation\": null\n    }\n  ]\n}",
  "extraction": [
    {
      "outcome": "objective-SCORAD score",
      "intervention": "extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).",
      "comparator": "extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 13,
      "comparator_events": null,
      "comparator_group_size": 13,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5884950"
    },
    {
      "outcome": "chemokines CXCL9",
      "intervention": "extensively hydrolyzed whey-based formula with short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).",
      "comparator": "extensively hydrolyzed whey-based formula without (control) short-chain galacto-oligosaccharides/long-chain fructo-oligosaccharides (9:1) and Bifidobacterium breve M-16V (active).",
      "outcome_type": "continuous",
      "intervention_events": null,
      "intervention_group_size": 21,
      "comparator_events": null,
      "comparator_group_size": 20,
      "intervention_mean": null,
      "intervention_standard_deviation": null,
      "comparator_mean": null,
      "comparator_standard_deviation": null,
      "pmcid": "5884950"
    }
  ]
}